Cello Group plc (LON:CLL)‘s stock had its “buy” rating reaffirmed by stock analysts at N+1 Singer in a note issued to investors on Tuesday. They presently have a GBX 128 ($1.67) price objective on the stock, up from their previous price objective of GBX 127 ($1.66). N+1 Singer’s price objective points to a potential upside of 19.63% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on the stock. Cenkos Securities Ltd reissued a “buy” rating on shares of Cello Group plc in a research report on Wednesday, September 14th. Peel Hunt reissued a “buy” rating and set a GBX 130 ($1.70) price target on shares of Cello Group plc in a research report on Tuesday, July 26th.

Shares of Cello Group plc (LON:CLL) remained flat at GBX 107.00 during midday trading on Tuesday. The stock had a trading volume of 145,983 shares. Cello Group plc has a 12 month low of GBX 77.10 and a 12 month high of GBX 115.00. The company’s market cap is GBX 92.89 million. The company’s 50-day moving average price is GBX 104.12 and its 200-day moving average price is GBX 97.73.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/cello-group-plc-cll-stock-rating-reaffirmed-by-n1-singer.html

The business also recently announced a dividend, which will be paid on Friday, November 4th. Stockholders of record on Thursday, October 6th will be given a GBX 1 ($0.01) dividend. The ex-dividend date of this dividend is Thursday, October 6th. This represents a dividend yield of 0.94%.

Cello Group plc Company Profile

Cello Group plc is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company’s pharmaceutical and healthcare clients.

Receive News & Ratings for Cello Group plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Group plc and related companies with MarketBeat.com's FREE daily email newsletter.